Karuna Therapeutics Inc. (KRTX) Misses Q3 EPS by 27c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Karuna Therapeutics Inc. (KRTX) Misses Q3 EPS by 27c

Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates

November 3, 2022 6:30 AM EDT

Initiated the Phase 3 ADEPT-1 trial of KarXT in Alzheimers disease psychosis in the third quarter of 2022

Phase 3 EMERGENT-3 trial completed enrollment in the fourth quarter of 2022, with topline data anticipated in the first quarter of 2023

On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. Food & Drug Administration (FDA) in mid-2023

$1.2 billion in cash is expected to fund operations through the end of 2025

BOSTON--(BUSINESS WIRE)-- Karuna Therapeutics, Inc. (NASDAQ:... More